<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145116</url>
  </required_header>
  <id_info>
    <org_study_id>ASPHINA 509-BER-401-17</org_study_id>
    <nct_id>NCT03145116</nct_id>
  </id_info>
  <brief_title>Clinical Safety and Efficacy of CT ASPHINA 509 Lenses</brief_title>
  <acronym>UVEA509</acronym>
  <official_title>Clinical Safety and Efficacy of Hydrophilic Acrylic Intraocular Lenses - Retro Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical safety and efficacy of CT ASPHINA 509 IOLs after implantation
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment rate
  </why_stopped>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Actual">February 5, 2018</completion_date>
  <primary_completion_date type="Actual">February 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 to 18 months after surgery</time_frame>
    <description>Monocular best corrected distance visual acuity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CT ASPHINA 509</intervention_name>
    <description>Intraocular lens</description>
    <arm_group_label>509</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient informed of the consequences and constraints of the protocol and who has given
        his/her written informed consent;

          -  Patients of any gender

          -  Assured follow-up examinations

          -  Biometry measurement preferably compatible with the IOLMaster evaluation;

          -  IOL implanted into the capsular bag with IOL model CT ASPHINA 409MP (UVE material) in
             one eye with at least 12 months follow up at the time of the postop visit

          -  Patients who had uncomplicated (no peroperative complication) agedrelated cataract
             surgery in a healthy eye (beside clinically significant cataract)

        Exclusion Criteria:

          -  â€¢ BCVA not available preoperatively or better than 0.3 logMAR pre-op

               -  Patients unable to meet the limitations of the protocol or likely of
                  noncooperation during the trial

               -  Patients whose freedom is impaired by administrative or legal order

               -  Concurrent participation in another drug or device investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Augenklinink</name>
      <address>
        <city>Ahaus</city>
        <zip>12593</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

